TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell primingMithun Khattar,Keli Song,Stephen Grossman,Kristina Xega,Xingyue He,Neeraja Idamakanti,Dennis HuszarCANCER RESEARCH(2019)引用 15|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要